Intermittent cisplatin therapy for stage-III ovarian cancer patients following clinical remission

Citation
N. Umesaki et al., Intermittent cisplatin therapy for stage-III ovarian cancer patients following clinical remission, GYNECOL OBS, 47(2), 1999, pp. 139-143
Citations number
15
Categorie Soggetti
da verificare
Journal title
GYNECOLOGIC AND OBSTETRIC INVESTIGATION
ISSN journal
03787346 → ACNP
Volume
47
Issue
2
Year of publication
1999
Pages
139 - 143
Database
ISI
SICI code
0378-7346(1999)47:2<139:ICTFSO>2.0.ZU;2-L
Abstract
Intermittent cisplatin (CDDP) administration as consolidation therapy for s tage-III ovarian cancer was studied. No patients with residual disease at s urgery or at second-look operation or patients with <8 U/ml of CA125 after remission induction chemotherapy were enrolled in this study. Fifteen subje cts received intermittent chemotherapy, and 10 control patients did not. CD DP of 20 mg/m(2) for 5 days was administered every 3-4 months for 5 years. A significant increase in 5-year survival rate was found in the intermitten t chemotherapy group when compared with the control group. Side effects fro m the intermittent chemotherapy were controllable. Intermittent CDDP therap y seems to be an effective consolidation therapy for stage-ill ovarian canc er patients.